Leftagraph

Every financial statement,
one clean chart.

Search any US-listed company. Data straight from SEC filings.

PROBuild your own list with the screener

ULTRAGENYX PHARMACEUTICAL INC. (RARE) financial statements

Number look wrong? Tell us

Data table
PROBuild your own list with the screener

ULTRAGENYX PHARMACEUTICAL INC. (RARE), most recent 12 months reported: revenue $717.21M, net loss $585.97M, free cash flow -$489M. Latest balance sheet on file: liquid cash $292M. From SEC filings. Others in Pharmaceutical Preparations: EMERGENT BIOSOLUTIONS INC. · Kiniksa Pharmaceuticals International, plc · PACIRA BIOSCIENCES, INC. · Amphastar Pharmaceuticals, Inc. · BridgeBio Pharma, Inc. · NURIX THERAPEUTICS, INC. · ARROWHEAD PHARMACEUTICALS, INC. · Mirum Pharmaceuticals, Inc.

Stock screener

Watchlist